SCHEMBL2697746

SCHEMBL2697746

CC(C)(c1ccccc1)n1ccccc1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2B6 P20813 1/20 0.41
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
MITF O75030 1/20 0.36
TP53 P04637 1/20 0.36
RAB9A P51151 1/20 0.36
MAPK1 P28482 1/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 1/20 0.35
P2RX7 Q99572 1/20 0.35
CYP2C19 P33261 1/20 0.34
HIF1A Q16665 1/20 0.34
ALDH1A1 P00352 3/20 0.33
HDAC4 P56524 2/20 0.33
HDAC2 Q92769 2/20 0.33
HDAC8 Q9BY41 2/20 0.33
TAAR1 Q96RJ0 1/20 0.33
ALOX15 P16050 1/20 0.33
HDAC3 O15379 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL782929 0.79 LMNA (0.37) LMNASMN1; SMN2NPC1MITFTP53
SCHEMBL20889885 0.75 LMNA (0.35) LMNASMN1; SMN2NPC1MITFTP53
SCHEMBL10883829 0.75 LMNA (0.35) LMNASMN1; SMN2NPC1MITFTP53
SCHEMBL21081452 0.72 NPC1 (0.36) LMNASMN1; SMN2NPC1MITFTP53
SCHEMBL27453821 0.72 CYP2B6 (0.48) CYP2B6MAPK1MAPTKMT2ACYP2C19
SCHEMBL9813292 0.71 KCNN4 (0.50) LMNASMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL1703209 0.70 HSD17B10 (0.39) LMNASMN1; SMN2NPC1MITFTP53
SCHEMBL15348173 0.68 POLB (0.33) LMNASMN1; SMN2NPC1MITFTP53
SCHEMBL22792122 0.67 NPC1 (0.33) LMNASMN1; SMN2NPC1MITFTP53
SCHEMBL21961168 0.66 NPC1 (0.35) LMNASMN1; SMN2NPC1MITFTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US disclosed
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-02-23 US disclosed
US-8088771-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 CYP2B6 2859/4885LMNA 1594/4885SMN1; SMN2 3414/4885
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 CYP2B6 2859/4885LMNA 1594/4885SMN1; SMN2 3414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.